000 02574na a2200229 4500
003 PC14457
005 20180417112924.0
008 130622s2011 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _9162
_aLópez Medrano, Francisco
_eEnfermedades Infecciosas
245 0 0 _aFactors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain
_h[artículo]
260 _bClinical Microbiology and Infection,
_c2011
300 _a17(5):738-746.
500 _aFormato Vancouver: Viasus D, Paño Pardo JR, Pachón J, Campins A, López Medrano F, Villoslada A, et al. Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect. 2011;17(5):738-46.
501 _aPMID: 20825436
504 _aContiene 41 referencias.
520 _aThe risk factors for complications in patients with influenza A (H1N1)v virus infection have not been fully elucidated. We performed an observational analysis of a prospective cohort of hospitalized adults with confirmed pandemic influenza A (H1N1)v virus infection at 13 hospitals in Spain, between June 12 and November 10, 2009, to identify factors associated with severe disease. Severe disease was defined as the composite outcome of intensive-care unit (ICU) admission or in-hospital mortality. During the study period, 585 adult patients (median age 40 years) required hospitalization because of pandemic (H1N1) 2009. At least one comorbid condition was present in 318 (54.4%) patients. Pneumonia was diagnosed in 234 (43.2%) patients and bacterial co-infection in 45 (7.6%). Severe disease occurred in 75 (12.8%) patients, of whom 71 required ICU admission and 13 (2.2%) died. Independent factors for severe disease were age < 50 years (OR, 2.39; 95% CI, 1.05-5.47), chronic comorbid conditions (OR, 2.93; 95% CI, 1.41-6.09), morbid obesity (OR, 6.7; 95% CI, 2.25-20.19), concomitant and secondary bacterial co-infection (OR, 2.78; 95% CI, 1.11-7) and early oseltamivir therapy (OR, 0.32; 95% CI 0.16-0.63). In conclusion, although adults hospitalized for pandemic (H1N1) 2009 suffer from significant morbidity, mortality is lower than that reported in the earliest studies. Younger age, chronic comorbid conditions, morbid obesity and bacterial co-infection are independent risk factors for severe disease, whereas early oseltamivir therapy is a protective factor.
710 _96
_aServicio de Medicina Interna
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc14457.pdf
_ySolicitar documento
942 _2ddc
_cART
_n0
999 _c14457
_d14457